Silexion Therapeutics Corp 8-K

What Happened

• Silexion Therapeutics Corp reconvened an extraordinary general meeting on March 23, 2026 (originally adjourned March 16, 2026 for lack of quorum). Holders of 1,216,369 ordinary shares (about 36.6% of issued and outstanding shares) were present in person or by proxy. Under Article 21.3 of the Company’s Articles, after a half hour lapse without a quorum, the shareholders present constituted a quorum and the meeting proceeded.
• Shareholders voted on two proposals and neither passed:
  • Proposal 1 — Authorized Share Capital Increase: failed (461,249 votes in favor (38.2%), 744,775 against (61.8%), 10,345 abstentions).
  • Proposal 2 — Evergreen Increase to the 2024 Equity Incentive Plan: failed (486,671 votes in favor (40.7%), 709,115 against (59.3%), 20,583 abstentions).

Key Details

• Shares present: 1,216,369 ordinary shares (~36.6% of issued/outstanding).
• Authorized capital change proposed: add 50,000,000 ordinary shares — increase from US$121,500 (9,000,000 shares at US$0.0135 par) to US$796,500 (59,000,000 shares at US$0.0135 par).
• Equity plan change proposed: amend 2024 Equity Incentive Plan (effective Jan 1, 2026) to raise the annual “evergreen” addition from 5% to an amount that yields a 10% aggregate pool of issued and outstanding shares on a fully diluted basis.
• Vote requirement: both proposals required a simple majority of shareholders present per the Articles; neither received the required affirmative vote.

Why It Matters

• Because both proposals were rejected, the company’s authorized share capital and the existing limits under its 2024 Equity Incentive Plan remain unchanged — Silexion cannot issue the additional new shares or expand the automatic annual share additions described in the proposals.
• The voting results (roughly 60% against for each proposal among votes cast) reflect shareholder opposition to these specific increases at this meeting; the company may need to revisit capital or equity-plan changes if it wants these actions approved in the future.